On the recordFebruary 3, 2016
I was concerned that CMS finalized its Part B payment policy for biosimilars last year combining all biosimilars into one average sales price calculation and payment code.
Source
congress.govI was concerned that CMS finalized its Part B payment policy for biosimilars last year combining all biosimilars into one average sales price calculation and payment code.
Pitts expresses concern over CMS's payment policy for biosimilars potentially harming market entry.
Share
More from Joe Pitts
Today's hearing is especially timely as we learned startling news over the summer, confirming our worst fears, that the some of the most significant health insurers--UnitedHealth, Aetna, Humana--are opting out of Obamacare's health…
The time of 10 o'clock having arrived, I will call this subcommittee meeting to order.
I for one in a portion of my life when I was a boy lived in a household where we didn't have access to health care.